Calamos Advisors’s enGene Therapeutics Warrants ENGNW Stock Holding History

Calamos Advisors’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-148,290	Closed	-$418K	–	1223
2025 Q4	$418K	Sell	148,290 -1,710	-1%	-$3.9K	﹤0.01%	786
2025 Q3	$108K	Hold	150,000	–	–	﹤0.01%	851
2025 Q2	$118K	Hold	150,000	–	–	﹤0.01%	842
2025 Q1	$96K	Hold	150,000	–	–	﹤0.01%	826
2024 Q4	$128K	Hold	150,000	–	–	﹤0.01%	813
2024 Q3	$214K	Hold	150,000	–	–	﹤0.01%	787
2024 Q2	$209K	Hold	150,000	–	–	﹤0.01%	785
2024 Q1	$780K	Sell	150,000 -100,000	-40%	-$305K	﹤0.01%	671
2023 Q4	$213K	Buy	+250,000	New	+$192K	﹤0.01%	749

Other funds holding ENGNW

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

ICM

Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return

Calamos Advisors's ENGNW Position: Q1 2026 in Review

Calamos Advisors sold out of enGene Therapeutics Warrants (ENGNW) in Q1 2026, closing a stake of 148,290 shares — an estimated $418K sold.

Calamos Advisors first reported a position in ENGNW in Q4 2023 and held it in 9 quarters. The position peaked at $780K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

Calamos Advisors reported no remaining enGene Therapeutics Warrants position as of Q1 2026 after selling out during the quarter.
Calamos Advisors sold 148,290 enGene Therapeutics Warrants shares in Q1 2026, an estimated $418K.
Calamos Advisors first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 9 quarters.
Calamos Advisors's enGene Therapeutics Warrants position peaked at $780K in Q1 2024.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.